Novo Nordisk's Wegovy sells like hot cakes in the US – increases production
The obesity drug Wegovy from Novo Nordisk is selling so well in the US, that the supply chain is struggling to keep up, leading to a three-week delay.
.jpg)
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk's new obesity drug is so popular in the US, that the company is struggling to keep up with the current demand.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA makes historic ruling on biosimilar insulin
For subscribers
.jpg&w=384&q=75)
